Aprea Therapeutics (APRE) said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved "early disease control" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.
The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.
Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.
APR-1051 showed "robust" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated "significant" anti-tumor synergy, Aprea added.
Shares of Aprea were up 1.2% in recent trading.
Price: 1.66, Change: +0.02, Percent Change: +1.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.